ArticleFrontiers in psychiatry2026
Case Report: Severe adolescent-onset schizophrenia with Capgras syndrome and remission during clozapine-centered treatment after earthquake-related displacement and peer victimization.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adolescent first-episode psychosis may combine schizophrenia-spectrum, affective, trauma-related, and developmental features, and Capgras syndrome is uncommon in this age group. We report a confidentially de-identified case of a 16-year-old female high-school student with no previous psychiatric admission or known substance use who developed severe insomnia, reduced self-care, external auditory hallucinations, paranoid and referential ideation, Capgras-type misidentification of her father, and a multithemed bizarre delusional system after cumulative psychosocial stressors including earthquake-related displacement, relocation, school transition, peer exclusion, appearance-related mockery, and family-school conflict. Laboratory tests, brain magnetic resonance imaging, electroencephalography, substance screening, and child neurology consultation were unrevealing. DSM-5-TR schizophreniform disorder was the initial working diagnosis; bipolar disorder with psychotic features, schizoaffective disorder, brief psychotic disorder, trauma-related or dissociative phenomena, substance/medication-induced psychosis, autoimmune encephalitis, and temporal lobe epilepsy were considered. Risperidone- and olanzapine-based treatment produced partial but insufficient improvement. Clozapine was initiated at admission week 8 and titrated to 175 mg/day over approximately 4 weeks. Marked improvement was observed by week 2 of clozapine-centered treatment and remission by week 4. At admission week 12, the Clinical Global Impression-Severity score was 1, the Positive and Negative Syndrome Scale score was 45, and the Young Mania Rating Scale score was 4. At 8-month follow-up, the patient remained clinically stable on clozapine 175 mg/day, and the diagnosis was maintained as schizophrenia because the longitudinal course exceeded 6 months. This case highlights the diagnostic complexity of adolescent-onset psychosis with Capgras syndrome, the need to distinguish contextual stressors from primary etiology, and the cautious, monitored consideration of clozapine when severe schizophrenia-spectrum psychosis shows insufficient response to standard antipsychotic trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.